Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30206% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Patients Revenue by Year
Patients Revenue — Self-Pay & Out-of-Pocket Co-Pays ($M) ($M)
Natera Patients Revenue: $31.8M in FY2025, up 14.1% from a year earlier.
Latest, FY2025
31.8
Period ended Dec 31, 2025
Change on a year earlier
+14.1%
27.9 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (2026-02-27) ↗
Direct patient self-pay revenue and patient deductibles/co-insurance collections.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Patients Revenue — Self-Pay & Out-of-Pocket Co-Pays ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31.8 | +14.1% | Form 10-K (2026-02-27) ↗ |
| FY2024 | Dec 31, 2024 | 27.9 | -5.6% | Form 10-K (2026-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 29.5 | -14.6% | Form 10-K (2026-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 34.6 | +5.0% | Form 10-K (2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 32.9 | +1.0% | Form 10-K (2024-02-29) ↗ |
| FY2020 | Dec 31, 2020 | 32.6 | +3.4% | Form 10-K (2023-03-01) ↗ |
| FY2019 | Dec 31, 2019 | 31.5 | +60.1% | Form 10-K (2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 19.7 | +101.8% | Form 10-K (2021-02-26) ↗ |
| FY2017 | Dec 31, 2017 | 9.76 | +10.8% | Form 10-K (2020-03-02) ↗ |
| FY2016 | Dec 31, 2016 | 8.81 | – | Form 10-K (2019-03-15) ↗ |
Cite this data
StockData. (2026). Natera Patients Revenue ($M), annual FY2016–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/rev-payer-patients
See every metric in the Natera KPI table. Data updated Nov 2, 2026.